Zhang L, et al. - Researchers conducted a comprehensive evaluation of cancer clinicopathologic parameters as well as correlated these parameters with the pathological complete response (pCR) rate and the overall survival. During 2005–2016, 58 patients with triple-negative breast cancer (TNBC) of no special type who underwent a breast biopsy, neoadjuvant therapy, and mastectomy in the institution were involved. A new concept of tumor infiltrating lymphocyte volume (TILV) to precisely evaluate the tumor immunity was introduced. As compared to tumor infiltrating lymphocytes, TILV had a better predictive value for predicting both pCR and the overall survival in TNBC.